IOL Chemicals and Pharmaceuticals Limited (IOLCP.BO)
INR 60.95
(1.96%)
INR 60.95
(1.96%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 1.59 Billion INR | -3.4% |
| 2022 | 1.73 Billion INR | -18.23% |
| 2021 | 2.12 Billion INR | -60.98% |
| 2020 | 5.44 Billion INR | 5.28% |
| 2019 | 5.16 Billion INR | 46.13% |
| 2018 | 3.53 Billion INR | 354.02% |
| 2017 | 778.9 Million INR | 1322.03% |
| 2016 | 54.77 Million INR | 114.21% |
| 2015 | -385.5 Million INR | 48.9% |
| 2014 | -754.38 Million INR | -1584.33% |
| 2013 | 50.82 Million INR | 71.79% |
| 2012 | 29.58 Million INR | -22.1% |
| 2011 | 37.97 Million INR | 100.94% |
| 2010 | -4.04 Billion INR | -1468.93% |
| 2009 | 295.21 Million INR | 13.47% |
| 2008 | 260.17 Million INR | -11.28% |
| 2007 | 293.25 Million INR | 91.1% |
| 2006 | 153.45 Million INR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 342.9 Million INR | 3.63% |
| 2023 FY | 1.67 Billion INR | -3.4% |
| 2023 Q4 | 330.9 Million INR | 18.14% |
| 2023 Q3 | 280.1 Million INR | -42.26% |
| 2023 Q2 | 485.1 Million INR | -16.46% |
| 2023 Q1 | 580.7 Million INR | -30.2% |
| 2022 Q4 | 831.9 Million INR | 168.88% |
| 2022 Q2 | 205.8 Million INR | -54.07% |
| 2022 Q1 | 448.1 Million INR | 31.33% |
| 2022 FY | 1.73 Billion INR | -18.23% |
| 2022 Q3 | 309.4 Million INR | 50.34% |
| 2021 Q1 | 998.3 Million INR | -1.35% |
| 2021 Q3 | 480.8 Million INR | 45.7% |
| 2021 FY | 2.12 Billion INR | -60.98% |
| 2021 Q2 | 330 Million INR | -66.94% |
| 2021 Q4 | 341.2 Million INR | -29.03% |
| 2020 Q1 | 1.48 Billion INR | 16.13% |
| 2020 Q4 | 1.01 Billion INR | -34.75% |
| 2020 Q2 | 1.66 Billion INR | 11.85% |
| 2020 FY | 5.44 Billion INR | 5.28% |
| 2020 Q3 | 1.55 Billion INR | -6.66% |
| 2019 Q3 | 1.54 Billion INR | 21.22% |
| 2019 Q1 | 1.39 Billion INR | -4.95% |
| 2019 FY | 5.16 Billion INR | 46.13% |
| 2019 Q4 | 1.27 Billion INR | -17.21% |
| 2019 Q2 | 1.27 Billion INR | -8.52% |
| 2018 Q3 | 1.27 Billion INR | 75.97% |
| 2018 Q2 | 727.3 Million INR | 104.82% |
| 2018 Q1 | 355.1 Million INR | 27.96% |
| 2018 FY | 3.53 Billion INR | 354.02% |
| 2018 Q4 | 1.46 Billion INR | 14.55% |
| 2017 Q3 | 95.6 Million INR | 63.7% |
| 2017 FY | 778.9 Million INR | 1322.03% |
| 2017 Q4 | 277.5 Million INR | 190.27% |
| 2017 Q1 | 31.7 Million INR | -83.51% |
| 2017 Q2 | 58.4 Million INR | 84.23% |
| 2016 FY | 54.77 Million INR | 114.21% |
| 2016 Q4 | 192.2 Million INR | 1356.06% |
| 2016 Q3 | 13.2 Million INR | 4.76% |
| 2016 Q2 | 12.6 Million INR | 23.53% |
| 2016 Q1 | 10.2 Million INR | -35.91% |
| 2015 Q2 | -146.3 Million INR | 25.96% |
| 2015 Q4 | 15.91 Million INR | 127.63% |
| 2015 FY | -385.5 Million INR | 48.9% |
| 2015 Q1 | -197.59 Million INR | 36.13% |
| 2015 Q3 | -57.6 Million INR | 60.63% |
| 2014 FY | -754.38 Million INR | -1584.33% |
| 2014 Q4 | -309.36 Million INR | 3.61% |
| 2014 Q3 | -320.95 Million INR | -124.22% |
| 2014 Q2 | -143.14 Million INR | -850.05% |
| 2014 Q1 | 19.08 Million INR | 95.15% |
| 2013 Q4 | 9.77 Million INR | -26.22% |
| 2013 FY | 50.82 Million INR | 71.79% |
| 2013 Q1 | 12.55 Million INR | -89.34% |
| 2013 Q2 | 15.23 Million INR | 21.35% |
| 2013 Q3 | 13.25 Million INR | -13.0% |
| 2012 Q2 | 7.85 Million INR | -23.63% |
| 2012 Q3 | 6.51 Million INR | -17.05% |
| 2012 Q4 | 117.81 Million INR | 1708.09% |
| 2012 FY | 29.58 Million INR | -22.1% |
| 2012 Q1 | 10.28 Million INR | 0.0% |
| 2011 FY | 37.97 Million INR | 100.94% |
| 2010 FY | -4.04 Billion INR | -1468.93% |
| 2009 FY | 295.21 Million INR | 13.47% |
| 2008 FY | 260.17 Million INR | -11.28% |
| 2007 FY | 293.25 Million INR | 91.1% |
| 2006 FY | 153.45 Million INR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 5.75 Billion INR | 72.269% |
| Aurobindo Pharma Limited | 42.2 Billion INR | 96.216% |
| Glenmark Life Sciences Limited | 8.97 Billion INR | 82.217% |
| Granules India Limited | 6.81 Billion INR | 76.575% |
| Indoco Remedies Limited | 1.29 Billion INR | -23.539% |
| Achyut Healthcare Limited | 4.43 Million INR | -35880.171% |
| Ajanta Pharma Limited | 19.67 Billion INR | 91.885% |
| Alkem Laboratories Limited | 19.46 Billion INR | 91.795% |
| Alpa Laboratories Limited | 184.49 Million INR | -765.488% |
| Brooks Laboratories Limited | 14.44 Million INR | -10958.172% |
| AstraZeneca Pharma India Limited | 1.71 Billion INR | 7.028% |
| Bajaj HealthCare Limited | - INR | -Infinity% |
| Bliss GVS Pharma Limited | 1.23 Billion INR | -29.716% |
| Dr. Reddy's Laboratories Limited | 67.72 Billion INR | 97.642% |
| Eris Lifesciences Limited | 5.18 Billion INR | 69.184% |
| FDC Limited | 2.98 Billion INR | 46.528% |
| Glenmark Pharmaceuticals Limited | 6.5 Billion INR | 75.443% |
| Gufic Biosciences Limited | 1.32 Billion INR | -20.068% |
| Ind-Swift Laboratories Limited | 4.42 Billion INR | 63.878% |
| Ipca Laboratories Limited | 7.98 Billion INR | 79.991% |
| Jagsonpal Pharmaceuticals Limited | 508.13 Million INR | -214.25% |
| Krebs Biochemicals & Industries Limited | -151.95 Million INR | 1150.824% |
| Lasa Supergenerics Limited | -458 Million INR | 448.642% |
| Laurus Labs Limited | 3.94 Billion INR | 59.56% |
| Lupin Limited | 28.04 Billion INR | 94.306% |
| Mankind Pharma Limited | 21.51 Billion INR | 92.579% |
| Medicamen Biotech Limited | - INR | -Infinity% |
| Medico Remedies Limited | 100.3 Million INR | -1492.024% |
| Megasoft Limited | -121.1 Million INR | 1418.536% |
| NATCO Pharma Limited | 25.96 Billion INR | 93.849% |
| Piramal Pharma Limited | 4.55 Billion INR | 64.959% |
| RPG Life Sciences Limited | 2.29 Billion INR | 30.341% |
| Sigachi Industries Limited | 1.47 Billion INR | -8.339% |
| Sun Pharmaceutical Industries Limited | 104.3 Billion INR | 98.469% |
| Suven Pharmaceuticals Limited | 4.6 Billion INR | 65.345% |
| Syncom Formulations (India) Limited | 249.25 Million INR | -540.639% |
| Unichem Laboratories Limited | - INR | -Infinity% |
| Wanbury Limited | 569.71 Million INR | -180.28% |
| Windlas Biotech Limited | 1.29 Billion INR | -22.936% |
| ZIM Laboratories Limited | 253.82 Million INR | -529.085% |
| Zydus Lifesciences Limited | 43.1 Billion INR | 96.296% |
| Sun Pharma Advanced Research Company Limited | -4.11 Billion INR | 138.804% |
| Divi's Laboratories Limited | 33.08 Billion INR | 95.173% |
| Hester Biosciences Limited | 364.81 Million INR | -337.707% |
| Procter & Gamble Health Limited | 2.78 Billion INR | 42.685% |
| Amrutanjan Health Care Limited | 457.54 Million INR | -248.994% |
| Bal Pharma Limited | 233.9 Million INR | -582.659% |
| Strides Pharma Science Limited | 5.22 Billion INR | 69.444% |
| Venus Remedies Limited | 534.65 Million INR | -198.662% |
| Aarti Pharmalabs Limited | 3.12 Billion INR | 48.953% |
| Nectar Lifesciences Limited | 923.8 Million INR | -72.85% |
| Shilpa Medicare Limited | 1.36 Billion INR | -16.873% |
| Aarti Drugs Limited | 7.14 Billion INR | 77.663% |
| Suven Life Sciences Limited | -1.22 Billion INR | 230.264% |
| Ind-Swift Limited | 1.22 Billion INR | -30.249% |
| Valiant Laboratories Limited | - INR | -Infinity% |
| J. B. Chemicals & Pharmaceuticals Limited | 14.28 Billion INR | 88.82% |
| Solara Active Pharma Sciences Limited | -3.85 Billion INR | 141.444% |
| Themis Medicare Limited | 392.58 Million INR | -306.736% |
| Hikal Limited | 32.11 Million INR | -4872.906% |
| Torrent Pharmaceuticals Limited | 25.33 Billion INR | 93.697% |
| Sequent Scientific Limited | - INR | -Infinity% |
| Novartis India Limited | 626.5 Million INR | -154.876% |
| Wockhardt Limited | -670 Million INR | 338.328% |
| Jubilant Pharmova Limited | 5.18 Billion INR | 69.227% |
| Biofil Chemicals and Pharmaceuticals Limited | 9.06 Million INR | -17507.816% |
| Neuland Laboratories Limited | 5.31 Billion INR | 69.974% |
| Morepen Laboratories Limited | 4.17 Billion INR | 61.743% |
| Kilitch Drugs (India) Limited | 208.05 Million INR | -667.508% |
| Mangalam Drugs & Organics Limited | 27.45 Million INR | -5715.427% |